NCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
Clinical Trials
140 trialsNCT04785820 2026-03-27
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Hoffmann-La Roche
Phase 2 Completed
NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
NCT00628368 2026-02-10
Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Completed
NCT07363629 2026-01-23
Impact of Preserving Versus Ligating the Right Gastric Artery on Anastomotic Outcomes After McKeown Esophagectomy: A Randomized Controlled Trial
The First Hospital of Hebei Medical University
Phase NA Completed
NCT04045496 2025-12-29
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1 Completed
NCT05342636 2025-12-17
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT06549816 2025-12-15
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Seagen Inc.
Phase 1 Completed
NCT07236320 2025-11-19
Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
Sichuan Cancer Hospital and Research Institute
Phase NA Completed
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT05880082 2025-08-24
PPIO-004-EC001
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT03708328 2025-08-20
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT03797625 2025-07-23
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Fudan University
Phase 2 Completed
NCT04242199 2025-07-14
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT01351103 2025-06-13
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis
Phase 1 Completed
NCT04548440 2025-06-12
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Sun Yat-sen University
Phase 2 Completed
NCT03914443 2025-05-31
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
National Cancer Center, Japan
Phase 1 Completed
NCT04121286 2025-05-20
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Allist Pharmaceuticals, Inc.
Phase 1 Completed
NCT04704154 2025-04-18
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
Phase 2 Completed
NCT04925284 2025-04-04
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
Phase 1 Completed
NCT04732494 2025-01-31
AdvanTIG-203
BeiGene
Phase 2 Completed
NCT06775652 2025-01-15
ESCC
Sichuan Cancer Hospital and Research Institute
Phase 3 Completed
NCT05355168 2024-12-31
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Anhui Provincial Hospital
Phase 2 Completed
NCT04212598 2024-12-10
The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer
Wuhan University
Phase 2 Completed
NCT02647125 2024-11-26
A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC
Fudan University
Phase 2 Completed
NCT02844075 2024-11-15
Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)
Yonsei University
Phase 2 Completed
NCT06691503 2024-11-15
A Clinical Trial of Esophagectomy for Esophageal Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT03985046 2024-11-07
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
Fudan University
Phase 2 Completed
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT03469557 2024-10-23
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
BeiGene
Phase 2 Completed
NCT04713891 2024-09-24
A Study of KF-0210 in Advanced Solid Tumors Patients
Keythera (Suzhou) Pharmaceuticals Co. Ltd
Phase 1 Completed
NCT04721223 2024-09-19
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT06063941 2024-08-27
High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy
Xijing Hospital of Digestive Diseases
Phase NA Completed
NCT04839471 2024-07-08
BEAR
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT04435197 2024-07-03
PALACE-2
Ruijin Hospital
Phase 2 Completed
NCT04641871 2024-06-26
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03339843 2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2 Completed
NCT02830594 2024-02-20
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Completed
NCT04568200 2024-01-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT03600831 2024-01-09
Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma
Huai'an First People's Hospital
Phase 2/3 Completed
NCT06184841 2023-12-28
HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
Peking University Cancer Hospital & Institute
Phase 1 Completed
NCT02916511 2023-12-22
ESO-Shanghai9
Fudan University
Phase 2 Completed
NCT04187352 2023-11-24
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
CStone Pharmaceuticals
Phase 3 Completed
NCT03792347 2023-11-22
PALACE-1
Ruijin Hospital
Phase 1 Completed
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT05302011 2023-10-10
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT02971956 2023-09-21
Pembrolizumab in Refractory Advanced Esophageal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00003864 2023-06-15
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
Eastern Cooperative Oncology Group
Phase 2 Completed